AstraZeneca’s Onglyza ‘mortality’ risks noted by FDA reviewers

Eric Palmer

FDA staff have raised serious concerns about the safety of AstraZeneca's ahead of an advisory committee review Tuesday, which could result in a recommendation of a label change for as well as other drugs in the DPP4 inhibitor class. 

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS